Inhibitors Of Complement Activation
AssigneeGenentech, Inc.
InventorsMICHAEL FUNG, WILLIAM N.C. SUN, CECILY R. Y. SUN
Life of this patent
Estimating the term…
Abstract
The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.
Claims21
An inhibitor of complement activation which specifically binds factor D which at a molar ratio of about 1.5:1 (inhibitor:factor D) can substantially inhibit complement activation.
An inhibitor of complement activation which specifically binds to human factor D which at a molar ratio of less than 80:1 (inhibitor:factor D) can substantially completely inhibit complement activation.
An inhibitor of complement activation which binds to a region of human factor D between (and including) amino acid residue numbers Cys154 and Cys170.
The monoclonal antibody 166-32.
The hybridoma producing the monoclonal antibody 166-32, deposited at the American Type Culture Collection under Accession number HB-12476.
A monoclonal antibody or a fragment, analogue or homologue thereof, or a peptide, oligonucleotide, peptidomimetic or an organic compound which binds to the same epitope on factor D as the antibody 166-32.
A cell line producing the monoclonal antibody or fragment thereof which binds to the same epitope on factor D as the antibody 166-32.
The chimeric form, having a mouse variable region and a human constant region, of the monoclonal antibody 166-32.
The chimeric form, having a mouse variable region and a human constant region, of the Fab fragment of the monoclonal antibody 166-32.
Dependencies are inferred from the claim text.